Oligonucleotides comprising modified nucleosides
AssigneeSomaLogic Operating Co., Inc.
InventorsJeff Carter, Bharat Gawande, Nebojsa Janjic, Daniel Schneider
Life of this patent
Estimating the term…
Abstract
Polynucleotides, such as aptamers, comprising at least first one 5-position modified pyrimidine and at least one second 5-position modified pyrimidine are provided, wherein the first and second 5-position modified pyrimidines are different. Methods of selecting and using such polynucleotides, such as aptamers, are also provided.
Claims19
An aptamer comprising at least one first 5-position modified pyrimidine and at least one second 5-position modified pyrimidine, wherein the first 5-position modified pyrimidine and the second 5-position modified pyrimidine are different 5-position modified pyrimidines;
- wherein the first 5-position modified pyrimidine is a 5-position modified uridine and wherein the second 5-position modified pyrimidine is a 5-position modified cytidine;
- or
- wherein the first 5-position modified pyrimidine is a 5-position modified cytidine and wherein the second 5-position modified pyrimidine is a 5-position modified uridine;
- wherein the 5-position modified cytidine is PPdC and the 5-position modified uridine is TyrdU;
- or
- wherein the 5-position modified cytidine is PPdC and the 5-position modified uridine is PPdU;
- or
- wherein the 5-position modified cytidine is PPdC and the 5-position modified uridine is NapdU;
- or
- wherein the 5-position modified cytidine is PPdC and the 5-position modified uridine is ThrdU;
- or
- wherein the 5-position modified cytidine is NapdC and the 5-position modified uridine is NapdU;
- or
- wherein the 5-position modified cytidine is NapdC and the 5-position modified uridine is PPdU;
- or
- wherein the 5-position modified cytidine is NapdC and the 5-position modified uridine is ThrdU;
- or
- wherein the 5-position modified cytidine is NapdC and the 5-position modified uridine is MOEdU.
A composition comprising a plurality of polynucleotides, wherein each polynucleotide comprises at least one first 5-position modified pyrimidine and at least one second 5-position modified pyrimidine, wherein the first 5-position modified pyrimidine and the second 5-position modified pyrimidine are different 5-position modified pyrimidines;
- wherein the first 5-position modified pyrimidine is a 5-position modified uridine and wherein the second 5-position modified pyrimidine is a 5-position modified cytidine;
- or
- wherein the first 5-position modified pyrimidine is a 5-position modified cytidine and wherein the second 5-position modified pyrimidine is a 5-position modified uridine;
- wherein the 5-position modified cytidine is PPdC and the 5-position modified uridine is TyrdU;
- or
- wherein the 5-position modified cytidine is PPdC and the 5-position modified uridine is PPdU;
- or
- wherein the 5-position modified cytidine is PPdC and the 5-position modified uridine is NapdU;
- or
- wherein the 5-position modified cytidine is PPdC and the 5-position modified uridine is ThrdU;
- or
- wherein the 5-position modified cytidine is NapdC and the 5-position modified uridine is NapdU;
- or
- wherein the 5-position modified cytidine is NapdC and the 5-position modified uridine is PPdU;
- or
- wherein the 5-position modified cytidine is NapdC and the 5-position modified uridine is ThrdU;
- or
- wherein the 5-position modified cytidine is NapdC and the 5-position modified uridine is MOEdU.
A method for identifying one or more aptamers capable of binding to a target molecule comprising:
- (a) contacting a library of aptamers with the target molecule to form a mixture, and allowing for the formation of an aptamer-target complex, wherein the aptamer-target complex forms when an aptamer has affinity for the target molecule;
- (b) partitioning the aptamer-target complex from the remainder of the mixture (or enriching for the aptamer-target complex);
- (c) dissociating the aptamer-target complex;
- and
- (d) identifying the one or more aptamers capable of binding to the target molecule;
- wherein the library of aptamers comprises a plurality of polynucleotides, wherein each polynucleotide comprises at least one first 5-position modified pyrimidine and at least one second 5-position modified pyrimidine, wherein the first 5-position modified pyrimidine and the second 5-position modified pyrimidine are different 5-position modified pyrimidines;
- wherein the first 5-position modified pyrimidine is a 5-position modified uridine and wherein the second 5-position modified pyrimidine is a 5-position modified cytidine;
- or
- wherein the first 5-position modified pyrimidine is a 5-position modified cytidine and wherein the second 5-position modified pyrimidine is a 5-position modified uridine;
- wherein the 5-position modified cytidine is PPdC and the 5-position modified uridine is TyrdU;
- or
- wherein the 5-position modified cytidine is PPdC and the 5-position modified uridine is PPdU;
- or
- wherein the 5-position modified cytidine is PPdC and the 5-position modified uridine is NapdU;
- or
- wherein the 5-position modified cytidine is PPdC and the 5-position modified uridine is ThrdU;
- or
- wherein the 5-position modified cytidine is NapdC and the 5-position modified uridine is NapdU;
- or
- wherein the 5-position modified cytidine is NapdC and the 5-position modified uridine is PPdU;
- or
- wherein the 5-position modified cytidine is NapdC and the 5-position modified uridine is ThrdU;
- or
- wherein the 5-position modified cytidine is NapdC and the 5-position modified uridine is MOEdU.
Dependencies are inferred from the claim text.